Great Basin Granted Expanded Patent for Its Highly Sensitive AMPED Molecular Detection Technology

SALT LAKE CITY–(BUSINESS WIRE)–Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics
company, today announced that the United States Patent and Trademark
Office (USPTO) issued U.S. Patent 9,359,637 for the company’s AMPED
technology. The newly issued patent for systems and methods for signal
amplification, U.S. Patent 9,359,637, broadens coverage of the
invention—termed AMPED—to now include methods of use of the technology,
not just confined to product kits containing the proprietary signal
amplifying polymer, for detection of any diagnostic target of interest
such as proteins and nucleic acids.
“The AMPED technology is at the core of our uniquely low-cost and
powerful system, one that is capable of answering the ‘what is it?’
question with a low-cost, low-plex test, and the ‘what is causing it?’
question, identified by syndromic multiplex panels,” said Robert D.
Jenison, chief technology officer, Great Basin Scientific. “We are
pleased that the U.S. Patent Office has seen fit to offer us broad
protection as we believe the exceptional sensitivity of AMPED can
eventually be useful in fields beyond our current product focus of
Molecular Diagnostics.”
The AMPED amplification and detection method uses the Company’s
proprietary detection chip, which provides a visible result when the
target of interest is present. AMPED’s high sensitivity and specificity
will enable the direct detection of pathogens present in clinical
samples, even when present in small amounts, without requiring
polymerase chain reaction-based (PCR) target amplification, and when
implemented in future tests will make it possible for Great Basin to
provide PCR-like limits of detection at greatly reduced test times for
certain targets of interest. This patent further secures the
intellectual property behind Great Basin’s advanced molecular
diagnostics technology. With this patent grant, Great Basin now has 6
U.S. patents and 13 patents pending.
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that
commercializes breakthrough chip-based technologies. The Company is
dedicated to the development of simple, yet powerful, sample-to-result
technology and products that provide fast, multiple-pathogen diagnoses
of infectious diseases. The Company’s vision is to make molecular
diagnostic testing so simple and cost-effective that every patient will
be tested for every serious infection, reducing misdiagnoses and
significantly limiting the spread of infectious disease. More
information can be found on the company’s website at www.gbscience.com.
Forward-Looking Statements
This press release includes forward-looking statements regarding the
Company’s continuing business efforts related to its products, including
but not limited to intellectual property protection from granted
patents, use of our proprietary technologies and related statements.
Forward-looking statements involve risk and uncertainties, which could
cause actual results to differ materially, and reported results should
not be considered as an indication of future performance. These risk and
uncertainties include, but are not limited to: (i) our limited operating
history and history of losses; (ii) our ability to develop and
commercialize new products and the timing of commercialization; (iii)
our ability to obtain capital when needed; and (iv) other risks set
forth in the Company’s filings with the Securities and Exchange
Commission, including the risks set forth in the company’s Annual Report
on Form 10-K for the fiscal year ended December 31, 2015 and the
company’s Quarterly Report on Form 10-Q for the quarter ended March 31,
2016. These forward-looking statements speak only as of the date hereof
and Great Basin Scientific specifically disclaims any obligation to
update these forward-looking statements, except as required by law.